Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Avid Bioservices, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States, with significant operational facilities in California. Founded in 1981, the company has established itself as a leader in the development and manufacturing of monoclonal antibodies and other biologics, catering to the needs of biotechnology and pharmaceutical companies.
Avid Bioservices offers a comprehensive range of services, including process development, cGMP manufacturing, and analytical testing, all tailored to support the unique requirements of its clients. The company is recognised for its commitment to quality and innovation, which has positioned it favourably in the competitive landscape of contract development and manufacturing organisations (CDMOs). With a strong track record of successful partnerships and a focus on customer satisfaction, Avid Bioservices continues to drive advancements in biomanufacturing.
+6 vs industry average
Avid Bioservices’s score of 46 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for Avid Bioservices yet.
Avid Bioservices, headquartered in the United States, currently does not report any specific carbon emissions data for the latest year. However, the company is committed to achieving net-zero emissions across all scopes by 2050, as indicated by its Science Based Targets initiative (SBTi) commitment. This long-term target reflects Avid's dedication to addressing climate change and reducing its environmental impact.
As part of its climate strategy, Avid Bioservices has made a near-term commitment to net-zero emissions, although specific reduction targets or percentages have not been disclosed. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector, which is increasingly focusing on sustainability and carbon reduction initiatives.
While no emissions data is available, Avid's commitment to net-zero emissions demonstrates its proactive approach to climate responsibility and aligns with industry trends towards greater environmental accountability.
Access structured emission data, company specific factors and auditable source documents
2030
90% reduction in Scope 1
Avid Bioservices Inc commits to reduce absolute scope 1 and 2 GHG emissions 90.0% by 2030 from a 2024 base year
2050
90% reduction in Scope 1
Avid Bioservices Inc commits to maintain a minimum 90.0% absolute scope 1 and 2 GHG emissions reduction from 2030 through 2050 from a 2024 b…
2050
90% reduction in scope 3 upstream
Avid Bioservices Inc also commits to reduce absolute scope 3 GHG emissions 90.0% by 2050 from a 2024 base year.
See all 7 climate goals
Already have an account? Sign in now
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more